Drug · CHEMBL3545262
SACITUZUMAB GOVITECAN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. SACITUZUMAB GOVITECAN. Drugs and targets, record CHEMBL3545262. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL3545262
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- HRS7-SN38, HRS7-SN38-ANTIBODY-DRUG-CONJUGATE, HRS7SN38, IMMU-132, Sacituzumab govitecan hziy, Sacituzumab govitecan-hziy
- ChEMBL
- Open Targets' highest stage
- Approval, for 5 of its 48 diseases, from ATC, DailyMed, EMA Human Drugs, FDA, PMDA and TTD
- Open Targets
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| TACSTD2 | Tumor-associated calcium signal transducer 2 | Tumor-associated calcium signal transducer 2 binding agent | BINDING AGENT | https://conductscience.org/library/genes/4070 |
| TOP1 | DNA topoisomerase 1 | DNA topoisomerase I inhibitor | INHIBITOR | https://conductscience.org/library/genes/7150 |
Source ChEMBL
Diseases48
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 48Source Open Targets
See all 48 diseasesTrials140
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT05089734 | Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | 603 | 2025-01-14 | sacituzumab govitecan | Its name | ClinicalTrials.gov |
| NCT03901339 | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer | Phase 3 | 543 | 2024-10-21 | sacituzumab govitecan | Its name | ClinicalTrials.gov |
| NCT02574455 | Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) | Phase 3 | 529 | 2021-04-30 | sacituzumab govitecan | Its name | ClinicalTrials.gov |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | Phase 1/2 | 515 | 2021-04-06 | sacituzumab govitecan-hziy | Its name | ClinicalTrials.gov |
| NCT03964727 | Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors | Phase 2 | 227 | 2026-01-30 | sacituzumab govitecan | Its name | ClinicalTrials.gov |
| NCT04448886 | Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC | Phase 2 | 110 | 2025-05-30 | sacituzumab govitecan | Its name | ClinicalTrials.gov |
| NCT04958785 | Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer | Phase 2 | 92 | 2025-10-03 | sacituzumab govitecan | Its name | ClinicalTrials.gov |
| NCT03725761 | Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy | Phase 2 | 31 | 2025-04-24 | sacituzumab govitecan | Its name | ClinicalTrials.gov |
| NCT05113966 | Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer | Phase 2 | 30 | 2025-01-29 | sacituzumab govitecan-hziy | Its name | ClinicalTrials.gov |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | Phase 1/2 | 25 | 2024-01-16 | sacituzumab govitecan | Its name | ClinicalTrials.gov |
1 to 10 of 140
See all 140 trialsComparisons in its trials13
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Sacituzumab Govitecan (SG) vs Docetaxel: deaths from any cause | 168 of 299 | 187 of 304 | 603 | NCT05089734 | Trial comparisons |
| Sacituzumab Govitecan (SG) vs Docetaxel: serious adverse events | 137 of 296 | 124 of 288 | 584 | NCT05089734 | Trial comparisons |
| Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC): deaths from any cause | 234 of 272 | 238 of 271 | 543 | NCT03901339 | Trial comparisons |
| Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC): deaths from any cause | 201 of 267 | 222 of 262 | 529 | NCT02574455 | Trial comparisons |
| Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC): serious adverse events | 74 of 268 | 48 of 249 | 517 | NCT03901339 | Trial comparisons |
| Sacituzumab Govitecan vs Treatment of Physician's Choice (TPC): serious adverse events | 69 of 258 | 64 of 224 | 482 | NCT02574455 | Trial comparisons |
| Sacituzumab Govitecan + Pembrolizumab vs Sacituzumab Govitecan: deaths from any cause | 18 of 54 | 22 of 56 | 110 | NCT04448886 | Trial comparisons |
| Sacituzumab Govitecan + Pembrolizumab vs Sacituzumab Govitecan: Objective Response Rate | 15 of 52 | 10 of 52 | 104 | NCT04448886 | Trial comparisons |
| Sacituzumab Govitecan + Pembrolizumab vs Sacituzumab Govitecan: Clinical Benefit Rate | 26 of 52 | 26 of 52 | 104 | NCT04448886 | Trial comparisons |
| Sacituzumab Govitecan + Pembrolizumab vs Sacituzumab Govitecan: serious adverse events | 40 of 52 | 36 of 52 | 104 | NCT04448886 | Trial comparisons |
1 to 10 of 13
See all 13 comparisons in its trialsPapers from its trials55
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL3545262
GET https://conductscience.org/api/drugs/v1/CHEMBL3545262/diseases?page=2